Loading
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$39.905
−$0.165 · -0.41%
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Regular session
$39.905
−$0.165 · -0.41%
Regular session · ET · Market data may be delayed.
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Day range
Current $39.905
52-week range
Current $39.905
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
79
Undervalued
Sentiment
62
Bullish
Risk
26
Moderate Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Day range
Current $39.905
52-week range
Current $39.905
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 46.72B EUR | 44.29B EUR | 41.62B EUR | 40.56B EUR | 39.18B EUR |
| Cost of goods sold | 13.05B EUR | 13.21B EUR | 12.63B EUR | 11.88B EUR | 12.26B EUR |
| Gross profit | 33.67B EUR | 31.08B EUR | 28.99B EUR | 28.68B EUR | 26.92B EUR |
| Research and development | 7.84B EUR | 7.39B EUR | 6.51B EUR | 6.5B EUR | 5.69B EUR |
| Selling, general, and administrative | 10.24B EUR | 9.18B EUR | 8.93B EUR | 8.74B EUR | 9.56B EUR |
| Operating expenses | 24.07B EUR | 23.83B EUR | 22.03B EUR | 18.52B EUR | 18.79B EUR |
| Interest income | 331M EUR | 457.53M EUR | 530.5M EUR | 168.96M EUR | 3.13M EUR |
| Interest expense | 626M EUR | 622.58M EUR | 512.82M EUR | 384.8M EUR | 377.37M EUR |
| Depreciation and amortization | 5.68B EUR | 3.59B EUR | 4.43B EUR | 3.11B EUR | 3.35B EUR |
| Operating income | 9.6B EUR | 7.25B EUR | 6.96B EUR | 10.16B EUR | 8.13B EUR |
| Net income | 7.81B EUR | 5.56B EUR | 5.4B EUR | 8.37B EUR | 6.22B EUR |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$49.50
24.04% upsideCash distributions grouped by calendar year; partial years are marked.
$2.1953
2025 complete year+15.2% since 2021
2026 partial: $2.419
$1.906
2,021
$2.044
2,022
$1.903
2,023
$2.0369
2,024
$2.1953
2,025
$2.419
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 4, 2026 | $2.419Annual | May 4, 2026 | Jun 3, 2026 |
Dividend | May 9, 2025 | $2.1953Annual | May 9, 2025 | Jun 12, 2025 |
Dividend | May 9, 2024 | $2.0369Annual | May 10, 2024 | Jun 6, 2024 |
Dividend | May 30, 2023 | $1.903Annual | May 31, 2023 | Jun 23, 2023 |
Dividend | May 26, 2022 | $0.297Special | May 27, 2022 | Jun 27, 2022 |
Dividend | May 4, 2022 | $1.747Annual | May 5, 2022 | May 31, 2022 |
Ex-dividend May 4, 2026
$2.419
Annual
Record May 4, 2026 · Payment Jun 3, 2026
Ex-dividend May 9, 2025
$2.1953
Annual
Record May 9, 2025 · Payment Jun 12, 2025
Ex-dividend May 9, 2024
$2.0369
Annual
Record May 10, 2024 · Payment Jun 6, 2024
Ex-dividend May 30, 2023
$1.903
Annual
Record May 31, 2023 · Payment Jun 23, 2023
Ex-dividend May 26, 2022
$0.297
Special
Record May 27, 2022 · Payment Jun 27, 2022
Ex-dividend May 4, 2022
$1.747
Annual
Record May 5, 2022 · Payment May 31, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis International Equity ETFAVDE41M0.21%19.22B USD0.23%$89.745-0.06%
Fidelity Enhanced International ETFFENI35.81M0.31%11.47B USD0.28%$39.705+0.04%
VanEck Pharmaceutical ETFPPH33.54M3.27%1.04B USD0.36%$110.44-0.04%
First Trust Value Line Dividend Index FundFVD30.33M0.40%7.62B USD0.62%$47.945+0.60%
Invesco International Dividend Achievers ETFPID24.96M2.91%857.93M USD0.53%$21.78+0.31%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH19.23M1.87%1.03B USD0.13%$28.38+0.09%
GMO International Value ETFGMOI16.58M2.50%654M USD0.60%$39.24+0.15%
Brown Advisory Sustainable Value ETFBASV6.04M1.46%413.57M USD0.71%$30.635+0.31%Avantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDInvesco International Dividend Achievers ETFPIDPortfolio Building Block World Pharma and Biotech Index ETFPBPHGMO International Value ETFGMOIBrown Advisory Sustainable Value ETFBASVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
